Royalty Pharma insider files to sell 3,045 shares

Royalty Pharma plc filed a Form 144 reporting the proposed sale of 3,045 shares of Common Stock on 05/13/2026.

Rhea-AI Filing Summary

Royalty Pharma plc filed a Form 144 reporting the proposed sale of 3,045 shares of Common Stock on 05/13/2026. The notice lists Merrill Lynch, 225 Liberty Street, Floor 37, New York as the broker and references the vesting of restricted stock unit awards granted under the issuer equity compensation plan.

Insights

Compliance & Insider Transactions Specialist

Routine affiliate resale following RSU vesting; broker-listed sale of 3,045 shares.

The filing documents a proposed disposition of 3,045 shares of Common Stock dated 05/13/2026, tied to the vesting of restricted stock unit awards. The broker is listed as Merrill Lynch at 225 Liberty Street.

The notice is a regulatory disclosure of an intended sale method and quantity; timing and execution details beyond the listed date are not further detailed in the excerpt. Subsequent transaction reporting would show completion and actual proceeds.

Key Figures

Form type: Form 144 Shares proposed for sale: 3,045 shares CUSIP: 443274104 +1 more

4 metrics

Form type Form 144 insider resale notice

Shares proposed for sale 3,045 shares 05/13/2026

CUSIP 443274104 Common Stock identifier

Broker address floor 225 Liberty Street, Floor 37 Merrill Lynch, New York

Key Terms

restricted stock unit awards, Form 144, vesting

3 terms

restricted stock unit awards financial

"Vesting of restricted stock unit awards"

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

vesting financial

"05/13/2026 | Vesting of restricted stock unit awards"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filed for RPRX show?

The Form 144 shows a proposed sale of 3,045 shares of Royalty Pharma common stock, dated 05/13/2026, tied to RSU vesting under the company's equity compensation plan.

Who is the listed broker on the RPRX Form 144?

The broker listed is Merrill Lynch with address 225 Liberty Street, Floor 37, New York, as shown on the Form 144 filing for the proposed sale of 3,045 shares.

Why were the 3,045 RPRX shares available for sale?

The filing references the vesting of restricted stock unit awards granted under the issuer equity compensation plan, which made the 3,045 shares available for disposition on 05/13/2026.

Does the Form 144 indicate the sale was completed?

The Form 144 reports a proposed disposition dated 05/13/2026 for 3,045 shares. Completion and proceeds would be shown in subsequent transaction reports if and when the sale occurs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 05:28 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001405104
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Royalty Pharma plc
SEC File Number	001-39329
Address of Issuer	110 EAST 59TH STREET NEW YORK NEW YORK 10022
Phone	(212) 883-0200
Name of Person for Whose Account the Securities are To Be Sold	Norden Gregory
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	3045	161385.00	443274104	05/14/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/13/2026	Vesting of restricted stock unit awards	Royalty Pharma plc			3045	05/13/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	05/14/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Gregory Norden
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)